

Ipca Laboratories (IPCA IN)

**Q1FY27 Result
Update**

August 16, 2026

☒ Estimate Change | ☒ Target | ☐ Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	Buy		Buy	
Target Price	2,000		1,800	
Sales (INR mn)	109,640	121,003	106,562	118,054
% Chng.	2.9	2.5		
EBITDA (INR mn)	24,840	28,354	23,667	27,443
% Chng.	5.0	3.3		
EPS (INR)	58.0	66.7	54.3	64.2
% Chng.	6.8	3.9		

Key Data

IPCA.BO | IPCA IN

BSE Code	524494
NSE Code	IPCALAB
52-W High / Low	INR 1,944 / INR 1,251
Face Value	1
Sensex / Nifty	78,009 / 24,366
Market Cap	INR 440 bn / \$ 4,609 mn
Shares Outstanding	253.66 mn
3M Avg. Daily Value	INR 574.11 mn

Shareholding Pattern (%)

Promoters	44.72
FII's	10.73
Mutual Funds	31.15
Domestic Institutions	6.22
Public & Others	7.18
Promoter's Pledge (INR bn)	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	(5.8)	9.5	16.7	27.0
Relative	(6.9)	5.8	23.7	31.2

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	89,396	96,463	109,640	121,003
EBITDA (INR mn)	16,931	19,990	24,840	28,354
Margin (%)	18.9	20.7	22.7	23.4
PAT (INR mn)	7,377	11,411	14,721	16,914
EV (INR mn)	456,306	449,628	443,871	435,411
Total Debt (INR mn)	13,017	7,039	3,039	1,039
C&C Eq. (INR mn)	3,442	5,646	8,091	15,299
EPS (INR)	29.1	45.0	58.0	66.7
Gr. (%)	34.8	54.7	29.0	14.9
DPS (INR)	6.5	5.0	6.0	6.0
Yield (%)	0.4	0.3	0.3	0.3
RoE (%)	11.1	15.2	16.8	16.5
RoCE (%)	16.2	18.6	21.9	22.3
EV/Sales (x)	5.1	4.7	4.0	3.6
EV/EBITDA (x)	27.0	22.5	17.9	15.4
PE (x)	59.6	38.6	29.9	26.0
P/BV (x)	6.3	5.5	4.7	4.0

Strong beat; FY27 guidance raised

Quick Pointers

- Strong revenue growth in export segment
- FY27 revenue growth and margin guidance revise upwards.

IPCA reported strong EBITDA of INR 6.4bn (up 50% YoY), 23% above our estimates. Company has revised revenue growth upward to 14-16% vs 12-13% earlier and OPM to 23% vs 22% in FY27E post strong Q1. Our FY27E and FY28E EPS stand increased by 4-5% which factors in 14% revenue growth in FY27. Domestic formulation and branded generic business, which now contributes 46% of revenues and ~70% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady growth in domestic formulation are the key growth drivers. At CMP, the stock is trading at 16x EV/EBITDA and 25x PE on FY28E adjusted for Unichem stake. We maintain our "Buy" rating on stock with revised TP of INR 2,000/share; valuing at 30x P/E on FY28E.

Higher revenue growth across segments YoY: IPCA's revenues came in at INR 27.9bn, up 21% YoY. We est INR 25.4bn. Ex Unichem, revenues grew by 21% YoY. Domestic formulations growth was 13% YoY. Export formulation was up 34% YoY at INR 6bn above our est. Branded business was up by 16% YoY while generic business was up 27% YoY. Institutional business doubled YoY to INR 1.2bn. API business delivered strong sales growth up 30% YoY at INR 4.2bn. Export API was up 33% YoY whereas domestic API was up 20% YoY. Revenues from subsidiaries was at INR 6.7bn.

EBITDA beat aided by higher export formulation and GMs: Consolidated gross margins improved 135bps YoY and 36bps QoQ to 71%. There was forex gain to the tune of INR 316mn booked under other expenses. Adj for forex; other expenses were up 16% YoY. Staff cost was up 22% YoY. EBITDA adj for forex gain came in at INR 6.4bn, up 50% YoY; vs our est of INR 5.2bn. OPM came in at 22.9%, up 450bps YoY. Unichem margins at 11% (up 680bps YoY and 280bps QoQ). Adj for Unichem; EBITDA growth was at 41% YoY; GMs of 76.4% and 26.4% OPM. Adj PAT for forex came at INR 3.8bn with EPS of INR 15/share.

Quarter Summary

Y/e Mar	Q1'27E	Q1'27A	% Var.	Q1'26A	YoY gr. (%)
Net Sales (INR mn)	25,275	27,881	10.0	23,089	21.0
EBITDA (INR mn)	5,027	6,378	27.0	4,246	50.0
Margin (%)	19.9	22.9	300 bps	18.4	450 bps
PAT (INR mn)	2,902	4,019	38.0	2,332	72.0

Source: Company, PL

Conference Call Highlights:

Domestic: Chronic grew 17.2% vs. 8.9% for acute, with strong traction across Urology (+25%), CNS (+19%), CV/anti-diabetic (+17%), Derma (+17%), Ophthalmology (+17%) and Pain management (+13%). Anti-malarial declined 24% YoY and now contributes only ~1% of domestic business. Growth mix remained healthy: ~5% volume, ~4.5–5% price and ~2% new launches; volume growth continued to outpace IPM. Field force stood at ~7,000 MRs, with ~200 additions planned for new divisions.

Unichem: US business grew 9% YoY while Ipca US business grew by 27% YoY aided by higher shipments. API business grew 73% YoY to ~INR 580mn, supported by higher captive production. FY27E guidance retained at 10% revenue growth and 13% EBITDA margin. New filings across Europe, Australia, NZ, Canada and Chile should gradually diversify the portfolio and improve margins; approvals typically take ~1.5 years

US: Both IPCA and Unichem combined portfolio to launch ~7–8 products in the US, with 4–5 new filings annually. API source transfers from Unichem to IPCA are currently minimal, with some approvals already received; additional cost-reduction/source-change filings are being pursued with the USFDA. US growth potential seen at ~15–17% for Ipca US business, supported by new launches and portfolio optimisation.

Export formulations: Generic business ex institutional business remained the key growth driver, with Europe/UK growing 70% YoY; promotional branded ROW also delivered strong growth. Institutional business grew 107% YoY, partly boosted by ~INR 400Mn of March shipments delayed to April. Institutional business growth expected to normalize to single digit, with annual business estimated at ~INR 2.5-3bn.

API: Growth was a key contributor to the FY27E guidance upgrade, with capacity utilisation nearing limits at Ratlam. New API/intermediate capacity is being developed at Dewas and Wardha, alongside investments to shift existing intermediate manufacturing towards continuous processes

Other highlights: Freight costs increased sharply across key markets, including South America, the US and Europe, amid container shortages. FY27E capex guided at INR 7-8bn, focused on formulations, biotech and API/intermediate capacity expansion. Biotech pipeline comprises ~7 biosimilar candidates, with ~INR 1bn additional investment planned for pilot facilities and R&D in FY27. Two biosimilars have completed engineering batches, with validation underway; clinical development expected to commence from FY27E. Lyka Labs is expanding across animal health, critical care and IVF, with management expecting gradual improvement as these businesses scale. Consolidated Debt stood at ~INR 1.93bn

Exhibit 1: Quarterly Estimates

(INR Mn)	Q1FY27E	YoY gr. (%)	Q2FY27E	YoY gr. (%)	Q3FY27E	YoY gr. (%)	Q4FY27E	YoY gr. (%)
Sales	27,881	20.8	28,386	11.0	26,540	10.9	26,833	12.3
EBITDA	6,378	50.2	6,646	19.9	6,109	15.3	5,707	16.4
Margin (%)	22.9		23.4		23.0		21.3	
Adj. PAT	4,019	72.3	3,931	39.1	3,540	8.5	3,232	8.1

Source: Company, PL

Exhibit 2: 1QFY27 Result Overview (INR mn): EBITDA beat est aided by higher exports and GM

Y/e March	Q1FY27	Q1FY26	YoY gr. (%)	Q1FY27E	% Var	Q4FY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Net Sales	27,881	23,089	20.8	25,275	10.3	23,885	16.7	96,463	89,396	7.9
Raw Material	7,974	6,916	15.3	7,203	10.7	6,916	15.3	28,227	27,786	1.6
% of Net Sales	28.6	30.0		28.5		29.0		29.3	31.1	
Personnel Cost	6,016	5,432	10.7	6,029	(0.2)	5,330	12.9	21,602	19,840	8.9
% of Net Sales	21.6	23.5		23.9		22.3		22.4	22.2	
Others	7,514	6,495	15.7	7,015	7.1	6,737	11.5	26,645	24,839	7.3
% of Net Sales	26.9	28.1		27.8		28.2		27.6	27.8	
Total Expenditure	21,503	18,843	14.1	20,247	6.2	18,983	13.3	76,474	72,464	5.5
EBITDA	6,378	4,246	50.2	5,027	26.9	4,902	30.1	19,990	16,932	18.1
Margin (%)	22.9	18.4		19.9		20.5		20.7	18.9	
Depreciation	1,108	1,001	10.7	1,061	4.5	1,071	3.4	4,181	3,978	5.1
EBIT	5,270	3,245	62.4	3,966	32.9	3,831	37.6	15,808	12,953	22.0
Other Income	253	327	(22.7)	346	(27.0)	937	(73.1)	1,745	928	88.0
Forex	317	(82)		-		(63)		(204)	330	
Interest	119	185	(35.8)	200	(40.6)	202	(41.2)	759	849	(10.6)
PBT	5,721	3,305	73.1	4,113	39.1	4,503	27.1	16,590	13,362	24.2
Extra-Ord. Inc./Exps.	-	-		-		458		864	2,051	
Total Taxes	1,493	961	55.3	1,110	34.4	951	57.0	3,812	3,436	10.9
ETR (%)	26.1	29.1		27.0		21.1		23.0	25.7	
Reported PAT	4,228	2,344	80.4	3,002	40.8	3,094	36.7	11,914	7,875	51.3
Minority Interest	(209)	(12)		(100)		(103)		(503)	(499)	
Total Comprehensive Income	4,019	2,332	72.3	2,902	38.5	2,991	34.4	11,411	7,377	54.7


Source: Company, PL

Exhibit 3: Witness growth across segments YoY

Major sources of revenues	Q1FY27	Q1FY26	YoY gr. (%)	Q4FY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Domestic	11,735	10,372	13.1	9,577	22.5	41,661	38,306	8.8
Formulations	10,821	9,610	12.6	8,533	26.8	38,172	34,551	10.5
APIs	914	762	19.9	1,043	(12.4)	3,489	3,755	(7.1)
Exports	9,354	6,998	33.7	8,455	10.6	31,294	28,090	11.4
Formulations	6,030	4,496	34.1	6,053	(0.4)	20,826	19,186	8.5
APIs	3,324	2,502	32.9	2,402	38.3	10,469	8,904	17.6
Subsidiaries	6,689	5,620		5,741		23,096	22,617	2.1


Source: Company, PL

Exhibit 4: Better portfolio mix supports broad-based growth




Source: Company, PL

Exhibit 5: Chronic portfolio demand remains strong




Source: Company, PL

Exhibit 6: Momentum continues YoY




Source: Company, PL

Exhibit 7: Recovery in business YoY



Source: Company, PL

Exhibit 8: Margins improved by 450 bps YoY



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	89,396	96,463	109,640	121,003
YoY gr. (%)	16.0	7.9	13.7	10.4
Cost of Goods Sold	33,332	34,734	38,215	41,963
Gross Profit	56,064	61,729	71,425	79,040
Margin (%)	62.7	64.0	65.1	65.3
Employee Cost	19,840	21,602	23,956	26,465
Other Expenses	19,292	20,138	22,628	24,221
EBITDA	16,931	19,990	24,840	28,354
YoY gr. (%)	31.4	18.1	24.3	14.1
Margin (%)	18.9	20.7	22.7	23.4
Depreciation and Amortization	3,978	4,181	4,599	5,059
EBIT	12,953	15,808	20,241	23,295
Margin (%)	14.5	16.4	18.5	19.3
Net Interest	849	759	550	500
Other Income	1,258	1,541	1,417	1,400
Profit Before Tax	13,362	16,590	21,108	24,195
Margin (%)	14.9	17.2	19.3	20.0
Total Tax	3,436	3,812	5,699	6,533
Effective Tax Rate (%)	25.7	23.0	27.0	27.0
Profit After Tax	9,926	12,778	15,409	17,662
Minority Interest	-	-	-	-
Share Profit from Associate	(499)	(503)	(688)	(748)
Adjusted PAT	7,377	11,411	14,721	16,914
YoY gr. (%)	34.8	54.7	29.0	14.9
Margin (%)	8.3	11.8	13.4	14.0
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	7,377	11,411	14,721	16,914
YoY gr. (%)	34.8	54.7	29.0	14.9
Margin (%)	8.3	11.8	13.4	14.0
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	7,377	11,411	14,721	16,914
Equity Shares O/s (mn)	254	254	254	254
EPS (INR)	29.1	45.0	58.0	66.7

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	65,372	73,232	81,232	89,232
Tangibles	65,372	73,232	81,232	89,232
Intangibles	-	-	-	-
Acc: Dep / Amortization	23,612	27,793	32,392	37,452
Tangibles	23,612	27,793	32,392	37,452
Intangibles	-	-	-	-
Net Fixed Assets	41,760	45,439	48,839	51,780
Tangibles	41,760	45,439	48,839	51,780
Intangibles	-	-	-	-
Capital Work In Progress	6,218	7,731	7,731	7,731
Goodwill	906	828	828	828
Non-Current Investments	253	265	265	265
Net Deferred Tax Assets	(2,781)	(2,243)	(2,243)	(2,243)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	7,634	6,334	6,334	6,334
Inventories	25,604	27,310	30,331	33,487
Trade Receivables	18,738	20,143	22,748	25,115
Cash & Bank Balance	3,442	5,646	8,091	15,299
Other Current Assets	10,746	8,206	8,206	8,206
Total Assets	117,436	123,497	135,048	150,805
Equity				
Equity Share Capital	254	254	254	254
Other Equity	69,231	80,384	94,035	109,939
Total Network	69,485	80,638	94,289	110,193
Non-Current Liabilities				
Long Term Borrowings	5,432	1,091	1,091	1,091
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	7,585	5,948	1,948	(52)
Trade Payables	8,462	9,403	10,616	11,720
Other Current Liabilities	9,295	9,571	9,571	9,571
Total Equity & Liabilities	117,437	123,497	135,048	150,805

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	13,802	16,568	20,791	23,795
Add. Depreciation	3,978	4,181	4,599	5,059
Add. Interest	(849)	(759)	(550)	(500)
Less Financial Other Income	1,258	1,541	1,417	1,400
Add. Other	1,659	(1,491)	688	748
Op. Profit before WC Changes	18,591	18,498	25,528	29,102
Net Changes-WC	(1,765)	(2,940)	(4,493)	(4,503)
Direct Tax	(3,613)	(4,140)	(5,699)	(6,533)
Net Cash from Op. Activities	13,213	11,419	15,336	18,067
Capital Expenditures	(8,275)	(6,701)	(8,000)	(8,000)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
Net Cash from Invst. Activities	(8,275)	(6,701)	(8,000)	(8,000)
Issue of Share Cap. / Premium	-	-	-	-
Debt Changes	(933)	(6,030)	(4,000)	(2,000)
Dividend Paid	(1,015)	(524)	(1,758)	(1,758)
Interest Paid	79	985	550	900
Others	(3,476)	3,054	317	-
Net Cash from Fin. Activities	(5,344)	(2,515)	(4,891)	(2,858)
Net Change in Cash	(406)	2,204	2,445	7,209
Free Cash Flow	5,458	4,897	7,336	10,067

Source: Company, PL

Quarterly Financials (INR mn)

Y/e Mar	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Net Revenues	25,565	23,925	23,885	27,881
YoY gr. (%)	8.6	6.6	6.3	20.8
Raw Material Expenses	7,816	6,579	6,916	7,974
Gross Profit	17,749	17,346	16,969	19,908
Margin (%)	69.4	72.5	71.0	71.4
EBITDA	5,543	5,299	4,902	6,378
YoY gr. (%)	23.2	18.8	19.6	50.2
Margin (%)	21.7	22.1	20.5	22.9
Depreciation / Depletion	1,033	1,076	1,071	1,108
EBIT	4,510	4,223	3,831	5,270
Margin (%)	17.6	17.6	16.0	18.9
Net Interest	196	176	202	119
Other Income	185	237	874	569
Profit before Tax	4,498	4,283	4,503	5,721
Margin (%)	17.6	17.9	18.9	20.5
Total Tax	1,081	819	951	1,493
Effective Tax Rate (%)	24.0	19.1	21.1	26.1
Profit After Tax	3,418	3,464	3,552	4,228
Minority Interest	9	378	103	209
Share Profit from Associate	-	-	-	-
Adjusted PAT	2,826	3,263	2,991	4,019
YoY gr. (%)	23.1	31.5	341.0	72.3
Margin (%)	11.1	13.6	12.5	14.4
Extra Ord. Income / (Exp)	583	(177)	458	-
Reported PAT	3,408	3,086	3,449	4,019
YoY gr. (%)	48.5	24.4	26.4	72.3
Margin (%)	13.3	12.9	14.4	14.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,408	3,086	3,449	4,019
Avg. Shares O/s (mn)	-	-	-	-
EPS (INR)	13.4	12.2	13.6	15.8

Source: Company, PL

Key Financial Metrics


Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	29.1	45.0	58.0	66.7
CEPS	44.8	61.5	76.2	86.6
BVPS	273.9	317.8	371.7	434.3
FCF	21.5	19.3	28.9	39.7
DPS	6.5	5.0	6.0	6.0
Return Ratio (%)				
RoCE	16.2	18.6	21.9	22.3
ROIC	12.2	14.2	16.8	18.0
RoE	11.1	15.2	16.8	16.5
Balance Sheet				
Net Debt : Equity (x)	0.0	-0.1	-0.1	-0.2
Net Working Capital (Days)	146	144	141	141
Valuation (x)				
PER	59.6	38.6	31.9	27.0
P/B	6.3	5.5	4.7	4.1
P/CEPS	38.7	28.2	23.9	20.6
EV/EBITDA	5.1	4.6	4.1	3.7
EV/Sales	26.8	22.4	18.6	15.8
Dividend Yield (%)	0.4	0.3	0.3	0.3
FCFF Yield (%)	1.2	1.1	1.7	2.1
PEG Ratio	1.7	0.7	1.5	1.5

Source: Company, PL

Key Operating Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Domestic Formulations	34,551	38,172	42,944	47,668
Domestic API	3,755	3,489	3,838	4,222
Export Formulations	19,186	20,826	24,406	27,301
Export API	8,904	10,469	12,248	13,473

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	09-Jul-26	Buy	1800	1762
2	02-Jun-26	BUY	1800	1490
3	09-Apr-26	Buy	1800	1445
4	06-Mar-26	BUY	1800	1501
5	17-Feb-26	BUY	1710	1491
6	08-Jan-26	BUY	1600	1514
7	14-Nov-25	BUY	1600	1302
8	08-Oct-25	Accumulate	1525	1360
9	13-Aug-25	Accumulate	1525	1377
10	08-Jul-25	Accumulate	1525	1456

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Ajanta Pharma	BUY	3730	3436
2	Anthem Biosciences	Buy	850	779
3	Apollo Hospitals Enterprise	BUY	10000	8600
4	Aster DM Quality Care	BUY	920	842
5	Aurobindo Pharma	HOLD	1600	1589
6	Brigade Enterprises	BUY	785	503
7	Cipla	Accumulate	1450	1393
8	Divi's Laboratories	Accumulate	8600	8056
9	Dr. Reddy's Laboratories	Accumulate	1300	1183
10	Eris Lifesciences	BUY	1700	1425
11	Fortis Healthcare	BUY	1120	955
12	Global Health	BUY	1600	1406
13	HealthCare Global Enterprises	BUY	820	670
14	Indoco Remedies	Hold	325	225
15	Ipca Laboratories	Buy	1800	1762
16	J.B. Chemicals & Pharmaceuticals	Buy	2400	2135
17	Jupiter Life Line Hospitals	BUY	360	319
18	Krishna Institute of Medical Sciences	Buy	850	796
19	Lupin	Accumulate	2500	2364
20	Max Healthcare Institute	BUY	1175	1085
21	Narayana Hrudayalaya	Buy	2350	1920
22	Oberoi Realty	Accumulate	2100	1883
23	Prestige Estates Projects	BUY	1800	1595
24	Rainbow Children's Medicare	BUY	1900	1546
25	Sun Pharmaceutical Industries	BUY	2150	1991
26	Sunteck Realty	BUY	520	291
27	Torrent Pharmaceuticals	BUY	5500	4872
28	Zydus Lifesciences	Accumulate	1200	1191

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Param Desai MBA Finance, Mr. Kushal Shah CFP, Passed CFA Level I Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai MBA Finance, Mr. Kushal Shah CFP, Passed CFA Level I Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.